The Immuno-Oncology Integrated Community Oncology Network (IO-ICON) is an innovative collaboration of health care professionals, scientists, and industry. Established by cancer experts and Bristol-Myers Squibb, IO-ICON is working to help provide patients with access to cutting-edge Immuno-Oncology research in their own communities.

Evolving and Enhancing the Status Quo for the Over 80% of People With Cancer Who Receive Treatment in Their Own Communities

Network goals are to be:

- **VISIONARY:** seeing beyond the status quo to evolve and enhance community research
- **COLLABORATIVE:** working together to advance research with urgency
- **DATA FOCUSED:** gathering data to increase understanding and integrate knowledge into future research
- **OPERATIONALLY EFFICIENT:** operationalizing clinical trials by simplifying the process and providing education
- **PATIENT FOCUSED:** responding to changing patient needs

- **110+ members** across 8 community networks
- **Over 2,900 sites** in 29 states
- **2 million+ patients** reached annually

Connecting Community Oncology Networks to Advance the Science

IO-ICON brings together insights from:

- Community Oncologists
- Pharmacists
- Nurses
- Clinical Staff and Educators
- Immunologists
- Molecular Profiling and Bioinformatics Specialists
- Bristol-Myers Squibb R&D and Medical Representatives

Driving Clinical Research Through Data Generation

IO-ICON generates data via clinical trials and real-world analyses.

- **38+ Phase I-4 studies to date,** enrolling **4,500+ patients**

Tracking medicines in the "real world" to:
- Understand outcomes
- Better manage adverse events
- Uncover patient characteristics to inform treatment decisions

IO-ICON and Bristol-Myers Squibb share a common goal to advance cancer research, with the hope of improving patient outcomes and understand there is more to be done.